CD19 and B-cell acute lymphoblastic leukemia: Another Phase I trial is investigating FT819, an iPSC-derived, TCR-less CD19-CAR T-cell therapy for relapsed/refractory B-cell lymphomas, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia [121].